Zendal is committed to the creation of a biotechnological pole Galicia-North of Portugal

  • The biotechnology group based in Porriño includes in its strategic plan new facilities in Galicia and in the north of Portugal
  • With a budget of over 110 million, the group will build a new packaging plant and will expand production and technological infrastructures in Galicia, to which it will add its presence in Portugal, where it will build a new vaccine production and packaging plant in Paredes de Coura (Portugal) with a planned investment of 15 million euros
  • The Zendal group, whose products are already present in 65 countries, has increased its staff in 2020 by 20%
  • The group considers that the current moment is positive to take advantage of the synergies of the Euroregion and to establish a biotechnological pole Galicia-North of Portugal

Porriño, January 14, 2021. The Zendal group advances in its strategic plan and will built a new center in Portugal, specifically it will be located in Paredes de Coura, and it is expected to be finished in December 2021. This new facility will complete the large investment that the biotech company based in Porriño has planned in this town of Pontevedra, where it will build new spaces to expand its production and packaging capacity.

Regarding the new facilities planned in Portugal, it will be a plant that will serve to expand Zendal’s capacity in the production and packaging of human health viral vaccines.

It is expected that the work can begin with an initial staff of 30 people, of which at least 50% will have higher degrees, for which it will have the collaboration of vocational training centers, universities and technology centers in the north of Portugal.

In this sense, it is important to note that Zendal expanded its staff during 2020 at its Spanish facilities by 20%, an area, human resources, in which it expects to continue growing during the next year.

For the CEO, Andrés Fernández, “we have been working for many years with the aim of being an international reference in biotechnology and health. Being able to grow and to expand borders is part of that growth process of which we are proud, always having our origin in Galicia as the central base.
We consider that for Zendal the presence in the neighboring country is an opportunity that will allow us to reinforce our role as a reference in the manufacture of vaccines. We are at a key moment for the Euroregion where the Galicia-North Portugal pole can be the base for large biotechnological projects.”

Vitor Pereira, mayor of Paredes de Coura, underlined “Zendal’s decision to install this important vaccine factory in the municipality is a great new for Paredes de Coura, but also for Portugal. This decision is the result of 2 years of hard work in attracting investment, supported by relationships of trust, responsiveness and institutional speed with the CEO of Zendal. A path in which we were able to count on the institutional cooperation of the Government, included that of Prime Minister António Costa, who has always accompanied the process and supported our efforts. It is a victory for Paredes de Coura and a great achievement for the Euroregion”.

For his part, the Prime Minister of Portugal, António Costa, said in this regard: “This ZENDAL investment places Portugal in a strategic position in the face of health crises, such as the current one caused by COVID-19, ensuring the involvement of the entire chain value of the health sector. This project also highlights Portuguese skills and abilities in an area of high technological intensity and with a strong export profile. My congratulations to Zendal and the municipality of Paredes de Coura”.

Latest generation for Galicia production plants
The company’s strategic plan has as one of the medium-term objectives the development of an ambitious project for Galicia, where it plans to invest more than 110 million euros before 2025 within the framework of the Next Generation funds. This budget will allow the expansion of a new packaging plant as well as productive and technological infrastructures and warehouses for human and animal health products.

These advances that take place after the improvement and optimization of the current facilities in which 18 million have been invested in the last two years, have allowed the biopharmaceutical group to position itself internationally and to reach agreements with multinational companies for the manufacture of vaccines.